- About
- PsychU For You
- Topics
- Events
- Content
The Curious Case Of Metabolic Dysfunction In Schizophrenia: Who’s Susceptible & Why?
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
The Curious Case Of Metabolic Dysfunction In Schizophrenia: Who’s Susceptible & Why?
A recent article1 published in World Psychiatry evaluated the mid and long term metabolic side effects of 31 antipsychotic drugs and confirmed that antipsychotic drugs differ in their propensity to induce metabolic side effects. Given that patients with schizophrenia often need lifelong treatment, careful consideration should be given when choosing an antipsychotic. Join a multidisciplinary panel including two metabolic-expert psychiatrists, a psychiatric nurse practitioner, and a licensed social worker highlighting:
- The heightened metabolic risk in drug-naïve individuals, the added risk when treating with antipsychotics
- What cardiometabolic parameters are important to measure (and why)
- What can be done to mitigate metabolic risks when considering risk/benefit
- Education regarding how the brain and body process sugar and implications for energy production will be discussed
- Evolution of metabolic guidelines and where we are headed
Reference:- Burschinski A et al. World Psychiatry 2023; 22 :116-128
Christoph Correll, MD
Chair of the Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany. Professor of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, USA.
MoreProfessor Correll’s research and clinical work focus on the identification, characterization and treatment of youth with severe mental illness, including psychotic and mood disorders, spanning all disease stages from the prodrome to first and multi-episode illness and up to refractory illness. He further focuses on psychopharmacology, epidemiology, comparative effectiveness, meta-analyses, the risk–benefit evaluation of psychotropic medications, and the interface between physical health and mental health.
William Wirshing, MD
Clinical Professor of Psychiatry, Keck USC School of Medicine; and Medical Director of Exodus Recovery, Inc. in Los Angeles, CA
MoreDr. William Wirshing is a Clinical Professor of Psychiatry at the Keck USC School of Medicine and Medical Director of Exodus Recovery, Inc in Los Angeles, where he provides psychiatric and chemical dependency care. His 40-year career has focused on the treatment of persons with schizophrenia and in particular the toxic consequences of putative antipsychotic compounds. Dr. Wirshing and his co-investigators at UCLA and the West Los Angeles VA Medical Center, pioneered the early studies leading to the discovery of metabolic side effects that became a veritable hallmark of the newer class of agents. His findings led to the development of the American Psychiatric Association and American Diabetes Association consensus guideline to appropriately monitor patients on atypical antipsychotic agents.
Michael Townsend, MA, LSW/LCSW
Deputy Chief Executive Officer, Gateway Counseling Center
MoreMr. Townsend, is the Deputy Chief Executive Officer at Gateway Counseling Center where he assists the Chief Executive Officer (CEO) with managing and directing the organization towards its primary objectives, serves as a member of the Boardof Directors, as well as the Chair of Audit Committee of the Mental Health Association in New York, and is also the President of GCC Transportation, LLC, which directs transportation services to the transit disabled and medically frail.
Darcy Leon, PMHNP-BC
Psychiatric Nurse Practitioner
MoreDarcy Leon is a psychiatric nurse practitioner currently working in outpatient psychiatry in Tarrytown, NY. She specializes in the treatment of mood disorders, traumatic brain injury, substance use disorders, and treatment-refractory psychiatric illnesses. Darcy also has a specific interest in psychodynamic psychopharmacology, which she employs to better connect patients with the ways their personal experiences interact with medication treatments.
Laura Brennan, PhD (OPDC)
Medical Science Liaison
Christoph Correll, MD, William Wirshing, MD, Michael Townsend MA, LMSW and Darcy Leon, PMHNP-BC are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Laura Brennan, PhD is a paid employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Upcoming Events
Registration
- PsychU For You
